NIOX Group plc is a dedicated diagnostics and management company focused on asthma. Our market-leading NIOX® products are used by physicians around the world to help improve asthma diagnosis and management, and we support our customers with dedication to outstanding customer service and after sales support.
Our purpose is to improve the quality of life for millions of people suffering from asthma.
As the leading provider of point-of-care FeNO diagnosis and management products we are making good progress, helping healthcare professionals manage their patients’ asthma.
We believe every asthma patient should have access to the best care. To help achieve this, we are working hard to provide our customers with outstanding support, while devoting ourselves to developing the next generation of NIOX® innovations.
The Company was established in 2006, and in 2014 we completed an initial public offering on the London Stock Exchange. A year later, we acquired the NIOX® range of products, broadening our portfolio.
With effect from 1 September 2022, the name of the Company was changed from Circassia Group plc to NIOX Group plc (“NIOX”).
NIOX is now dedicated to asthma point-of-care diagnosis and management, with a clear mission, market-leading products and strong commercial organization dedicated to providing outstanding customer support.